Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.
Description
The Illumina DRAGEN Secondary Analysis system offers precise, thorough, and highly efficient processing of next-generation sequencing data. Utilizing a graph reference genome alongside machine learning techniques, it achieves remarkable accuracy. The workflow is exceptionally streamlined, capable of completely analyzing a 34x whole human genome in approximately 30 minutes when using the DRAGEN server v4. Additionally, it enhances this workflow by compressing FASTQ file sizes by up to five times. This system is adept at analyzing a variety of NGS data types, including whole genomes, exomes, methylomes, and transcriptomes. It is designed to be compatible with the user's preferred platform and is scalable to meet varying requirements. DRAGEN analysis consistently ranks as a leader in accuracy for both germline and somatic variant detection, as evidenced by its performance in industry competitions conducted by precisionFDA. This advanced analysis solution empowers laboratories of all sizes and specialties to maximize the potential of their genomic datasets. Moreover, the implementation of highly adaptable field-programmable gate array (FPGA) technology allows DRAGEN to deliver hardware-accelerated genomic analysis algorithms, further enhancing its performance. Such advancements position DRAGEN as a vital tool in the ever-evolving field of genomics.
API Access
Has API
API Access
Has API
Integrations
Amazon Web Services (AWS)
BaseSpace Sequence Hub
Correlation Engine
Emedgene
Google Cloud Platform
Illumina Connected Analytics
Integrations
Amazon Web Services (AWS)
BaseSpace Sequence Hub
Correlation Engine
Emedgene
Google Cloud Platform
Illumina Connected Analytics
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Genomenon
Country
United States
Website
www.genomenon.com/pharma/
Vendor Details
Company Name
Illumina
Country
United States
Website
www.illumina.com/products/by-type/informatics-products/dragen-secondary-analysis.html